Objective
Massive perivillous fibrin deposition (MPFD) is associated with serious complications of pregnancy including recurrent spontaneous abortion, fetal growth restriction and fetal demise. The aim of the study was to determine if maternal plasma concentrations of angiogenic/anti-angiogenic factors in MPFD differ from uncomplicated pregnancies.
Study Design
This retrospective longitudinal case-control study included MPFD cases (n=10) and control patients (n=175) with uncomplicated pregnancies who were enrolled in a longitudinal study and delivered at term. Serial plasma concentrations of placental growth factor (PlGF), soluble endoglin (sEng), and soluble vascular endothelial growth factor receptor (sVEGFR) -1 and -2 were determined by ELISA (cases, n=28 samples; controls, n=751 samples). Individual analyte concentrations were averaged across gestational length at specimen collection intervals. Linear mixed models were used to test for differences in log transformed mean analyte concentrations both overall and as a function of time.
Results
1) Patients with MPFD had a lower mean plasma PlGF concentration (p=0.03) and higher mean plasma concentrations of sVEGFR-1 and sEng (both p<0.01) than controls, adjusted for potential confounders; 2) the mean plasma concentration of PlGF differed further among cases and controls as a function of gestational age interval (p<0.0001); however, mean sVEGFR-1 and sEng group differences as a function of gestational age interval approached but did not reach significance (p=0.09, p=0.11, respectively); 3) patients with MPFD had lower mean plasma concentrations of PlGF/sVEGFR-1 (p<0.0001) and PlGF/sEng (p<0.001); both of these relationships differed further as a function of gestational age interval (both p<0.0001); and 4) differences in mean sVEGFR-1, sEng, and the ratios of PlGF/sVEGFR-1 and PlGF/sEng were observed before 20 weeks of gestation.
Conclusion
An imbalance of angiogenic/anti-angiogenic factors is present in patients with MPFD prior to the diagnosis. We propose that these changes participate in the mechanisms responsible for adverse pregnancy outcomes in patients with MPFD.